These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 20979491)

  • 1. Management of Clostridium difficile infection: thinking inside and outside the box.
    Gerding DN; Johnson S
    Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Clostridium difficile infection.
    Gerding DN; Muto CA; Owens RC
    Clin Infect Dis; 2008 Jan; 46 Suppl 1():S32-42. PubMed ID: 18177219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?
    Pepin J
    Clin Infect Dis; 2008 May; 46(10):1493-8. PubMed ID: 18419481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, diagnosis and treatment of Clostridium difficile infection.
    Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
    Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
    J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.
    Johnson S
    J Infect; 2009 Jun; 58(6):403-10. PubMed ID: 19394704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?
    Kuijper EJ; Wilcox MH
    Clin Infect Dis; 2008 Jul; 47(1):63-5. PubMed ID: 18491959
    [No Abstract]   [Full Text] [Related]  

  • 11. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Clostridium difficile infection: causality and therapeutic approaches.
    Johnson S
    Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S33-6. PubMed ID: 19303567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
    Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline for the treatment of severe Clostridium difficile infection.
    Larson KC; Belliveau PP; Spooner LM
    Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium difficile infection in the intensive care unit.
    Leclair MA; Allard C; Lesur O; Pépin J
    J Intensive Care Med; 2010; 25(1):23-30. PubMed ID: 20034951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
    McFarland LV; Elmer GW; Surawicz CM
    Am J Gastroenterol; 2002 Jul; 97(7):1769-75. PubMed ID: 12135033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.